Skip to content
Research/Hormone Optimization/Estradiol Cypionate

Estradiol Cypionate

Depo-Estradiol. Long-acting estradiol ester. Injectable HRT option with ~2-week activity.

Intelligence Profile

Safety Profile

Evidence Limitation Notice: The available evidence for estradiol cypionate safety is extremely limited. Most studies in the provided evidence focus on veterinary applications in cattle, with minimal human clinical data. This assessment is therefore incomplete and should not be considered comprehensive.

Known Side Effects

The evidence provided does not contain specific safety data for estradiol cypionate in humans. One reference from 2006 mentions estradiol cypionate but provides no safety details. The clinical trials listed focus on different estradiol formulations or combinations, making it difficult to extrapolate safety information specific to estradiol cypionate.

Evidence gap: No human studies documenting side effects of estradiol cypionate were identified in the provided evidence.

Contraindications

No specific contraindications for estradiol cypionate are documented in the provided evidence. This represents a significant evidence gap for clinical decision-making.

Drug Interactions

The provided evidence does not contain information about drug interactions with estradiol cypionate. Several clinical trials mention combination therapies (progesterone/estradiol, letrozole with estradiol valerate), but these involve different estradiol formulations and do not provide interaction data specific to estradiol cypionate.

Populations That Should Avoid It

The evidence does not specify which populations should avoid estradiol cypionate. This is a critical safety information gap.

Clinical Trial Context

While several clinical trials are listed involving estradiol compounds, none specifically evaluate estradiol cypionate safety:

  • Most completed trials focus on different estradiol formulations
  • One Phase 2 trial (NCT05143723) compares progesterone/estradiol to GnRH agonist but uses unspecified estradiol formulations
  • Safety outcomes are not detailed for any of the listed trials

Important Disclaimer: This safety assessment is severely limited by lack of evidence. Healthcare providers should consult comprehensive prescribing information, established clinical guidelines, and additional literature before prescribing estradiol cypionate. Patients should discuss all potential risks and benefits with their healthcare provider based on their individual medical history and circumstances.

Evidence Quality: The evidence base for estradiol cypionate safety in humans is insufficient based on the provided sources. Most available data relates to veterinary applications, which cannot be directly applied to human safety assessment.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.